Details for Patent: 10,398,791
✉ Email this page to a colleague
Which drugs does patent 10,398,791 protect, and when does it expire?
Patent 10,398,791 protects PLUVICTO and is included in one NDA.
This patent has eighty-two patent family members in thirty-seven countries.
Summary for Patent: 10,398,791
| Title: | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| Abstract: | The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib). |
| Inventor(s): | Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike BAUDER-WÜST, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina BENESOVA |
| Assignee: | Novartis AG , Molecular Insight Pharmaceuticals Inc |
| Application Number: | US16/114,988 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; |
Drugs Protected by US Patent 10,398,791
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | 10,398,791 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,398,791
International Family Members for US Patent 10,398,791
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 4095130 | ⤷ Start Trial | CA 2024 00027 | Denmark | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | LUC00352 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | 301281 | Netherlands | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | PA2024522 | Lithuania | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | 2024C/528 | Belgium | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | 122024000038 | Germany | ⤷ Start Trial |
| European Patent Office | 4095130 | ⤷ Start Trial | CR 2024 00027 | Denmark | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
